ATE218368T1 - Medikament welches protein c aktivierendes peptid enthält - Google Patents

Medikament welches protein c aktivierendes peptid enthält

Info

Publication number
ATE218368T1
ATE218368T1 AT96901265T AT96901265T ATE218368T1 AT E218368 T1 ATE218368 T1 AT E218368T1 AT 96901265 T AT96901265 T AT 96901265T AT 96901265 T AT96901265 T AT 96901265T AT E218368 T1 ATE218368 T1 AT E218368T1
Authority
AT
Austria
Prior art keywords
activation peptide
containing protein
medication containing
protein
pharmaceutical preparation
Prior art date
Application number
AT96901265T
Other languages
English (en)
Inventor
Johann Eibl
Ludwig Pichler
Hans-Peter Schwarz
Peter Turecek
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of ATE218368T1 publication Critical patent/ATE218368T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT96901265T 1995-01-20 1996-01-12 Medikament welches protein c aktivierendes peptid enthält ATE218368T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/375,777 US5571786A (en) 1990-08-16 1995-01-20 Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
PCT/EP1996/000126 WO1996022108A1 (en) 1995-01-20 1996-01-12 The use of activated protein c for preparing a pharmaceutical preparation

Publications (1)

Publication Number Publication Date
ATE218368T1 true ATE218368T1 (de) 2002-06-15

Family

ID=23482293

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0901196A AT409822B (de) 1995-01-20 1996-01-12 Verwendung von aktiviertem protein c zur herstellung einer pharmazeutischen präparation
AT96901265T ATE218368T1 (de) 1995-01-20 1996-01-12 Medikament welches protein c aktivierendes peptid enthält

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0901196A AT409822B (de) 1995-01-20 1996-01-12 Verwendung von aktiviertem protein c zur herstellung einer pharmazeutischen präparation

Country Status (9)

Country Link
US (1) US5571786A (de)
EP (1) EP0804228B1 (de)
JP (1) JP3330953B2 (de)
AT (2) AT409822B (de)
CA (1) CA2209931A1 (de)
DE (1) DE69621591T2 (de)
DK (1) DK0804228T3 (de)
ES (1) ES2177755T3 (de)
WO (1) WO1996022108A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0975775T3 (da) 1997-04-23 2004-07-26 Vlaams Interuniv Inst Biotech Regulatorisk system til inducerbar ekspression af gener med lambdapromotorer
US6953568B1 (en) * 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
WO2000037022A2 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
US7282488B2 (en) * 2000-05-22 2007-10-16 The Johns Hopkins Univeristy Genetic engineering of vascular grafts to resist disease
EP1404412B1 (de) 2001-06-13 2012-03-21 The University of Sydney Protein C für die Wundheilung
AU2002354951A1 (en) * 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
WO2004050023A2 (en) 2002-11-27 2004-06-17 Dmi Biosciences, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
AU2013268725B2 (en) 2012-05-31 2017-02-16 Asahi Kasei Pharma Corporation Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
WO2014005183A1 (en) 2012-07-04 2014-01-09 The University Of Sydney Treatment of inflammatory skin disorders
ES2890675T3 (es) 2014-04-16 2022-01-21 Zz Biotech Llc APC para uso en el tratamiento de cicatrices cutáneas anormales
AU2015246656B2 (en) 2014-04-16 2020-06-18 Zz Biotech Llc Use of APC analogue for wound healing
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
US4658830A (en) * 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US4902614A (en) * 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US4908314A (en) * 1987-07-02 1990-03-13 American National Red Cross Protein C activator
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
DE3804600A1 (de) * 1988-02-13 1989-08-24 Basf Ag Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JP2774156B2 (ja) * 1989-09-05 1998-07-09 帝人株式会社 ヒトプロテインｃおよび／または活性化ヒトプロテインｃ様活性を有する蛋白
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation

Also Published As

Publication number Publication date
JPH11502508A (ja) 1999-03-02
DE69621591T2 (de) 2003-01-16
CA2209931A1 (en) 1996-07-25
ATA901196A (de) 2002-04-15
EP0804228A1 (de) 1997-11-05
DK0804228T3 (da) 2002-09-23
ES2177755T3 (es) 2002-12-16
DE69621591D1 (de) 2002-07-11
EP0804228B1 (de) 2002-06-05
JP3330953B2 (ja) 2002-10-07
US5571786A (en) 1996-11-05
AT409822B (de) 2002-11-25
WO1996022108A1 (en) 1996-07-25

Similar Documents

Publication Publication Date Title
AU649421B2 (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
ATE218368T1 (de) Medikament welches protein c aktivierendes peptid enthält
TW352384B (en) Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE68910892D1 (de) Arzneimittel zur Verhütung von sexuell übertragbaren Krankheiten.
SE8804570D0 (sv) New ciclosporin crystal form process for its produktion pharmaceutical compositions containing it and its use
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
MA24339A1 (fr) Procede de preparation de medicaments destines au traitement d'infections bacteriennes en pediaterie
DK160429C (da) N-heterocyclisk glycosid med antitumorvirkning, fremstilling deraf samt farmaceutisk praeparat indeholdende glycosidet
ZA963826B (en) A method of treatment of mania and bipolar disorder
DE3780644D1 (de) Glykopeptid-antibiotika.
AU1384995A (en) Human circulating cytokine cc-1
AU579593B2 (en) Novel peptides which are active on the central nervous system and have an action on the cholinergic system
CA2041380A1 (en) Use of protein c or activated protein c for preparing a pharmaceutical preparation
DK91092D0 (de)
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
FR2569111B1 (fr) Nouveaux medicaments contenant des tripeptides
HUT44035A (en) Process for producing new antibiotic bbm-1675 c and d of antitumor effect and pharmaceutical preparations containing these
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
BR9609801A (pt) Petídos cíclicos análogos de somatostina com atividade inibitória do desenvolvimento de hormónio
GB1361198A (en) Disulphide compounds and process for their manufa'ture
EP0723454A4 (de) Für die immun- und cns-therapir nutzbare, neuartige tripeptide
FI872459A7 (fi) Farmaseuttinen valmiste bakteeri-infektioiden hoitoon.
AU5381890A (en) Interferon for the use in the prevention or treatment of swine pneumonia or related bacterial diseases
FR2657005B1 (fr) Systeme d'enclouage pour le traitement des fractures notamment du type cervico-trochanteriennes et pertrochanteriennes.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee